Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
This is a phase I, randomized, safety and pharmacokinetic (PK) study of sorafenib given in
combination with capecitabine. The study will enroll two simultaneous cohorts; patients will
be randomly assigned to either Cohort A or Cohort B. A third cohort (C) may be added to the
protocol at a later date.